Table 3 Inflammation markers and infarct size in Obstructive-AMI and MINOCA patients, according to admission hyperglycemia

Inflammation markers (admission—T0)

 WBC N/µl, median (IQR)

10.5 (8.1–13.3)

9.2 (7.4–11.6)

 < 0.001

10.4 (8.1–14.9)

8.1 (6.6–10.1)

 < 0.001

ns

 Neutrophil N/µl, median (IQR)

7197 (5385–10,249)

6228 (4678–8623)

 < 0.001

7933 (5637–11,443)

5305 (4053–7361)

 < 0.001

ns

 Lymphocyte N/µl, median (IQR)

1710 (1187–2530)

1787 (1312–2496)

0.2

1736 (1165–2164)

1840 (1385–2310)

0.3

ns

 PLTs count × 10⁹ per L, median (IQR)

233 (193–282)

228 (189–275)

0.1

234 (195–287)

239 (200–289)

0.8

ns

 CRP mg/dL, median (IQR)

0.5 (0.2–1.4)

0.4 (0.2–0.8)

 < 0.001

0.5 (0.2–1.6)

0.3 (0.1–0.7)

0.04

ns

Inflammation markers (24 h—T1)

 WBC N/µl, median (IQR)

9.7 (7.9–12.3)

8.7 (7.0–10.9)

 < 0.001

7.9 (7.0–10.9)

7.4 (6.2–8.8)

0.04

0.008

 Neutrophil N/µl, median (IQR)

6935 (5344–9392)

5881 (4425–7730)

 < 0.001

5505 (3851–9122)

4590 (3519–6527)

0.08

0.026

 Lymphocyte N/µl, median (IQR)

1688 (1187 – 2219)

1839 (1376 –2407)

 < 0.001

2012 (1042 – 2419)

1817 (1367 – 2304)

0.9

ns

 CRP mg/dL, median (IQR)

1.1 (0.4 – 4.3)

0.7 (0.3 – 1.8)

 < 0.001

1.0 (0.4 – 2.3)

0.5 (0.2 – 1.0)

0.06

ns

Infarct size

 LVEDV ml, median (IQR)

108 (84 – 135)

100 (83 – 121)

0.003

80 (70 – 121)

89 (74 – 107)

0.7

0.016

 LV EF %, median (IQR)

47 (40 – 56)

55 (45 – 60)

 < 0.001

59 (50 – 61)

60 (53 – 62)

0.8

 < 0.001

 Peak hs Troponin ng/L, median (IQR)

6556 (959 – 35,531)

2936 (576 – 18,164)

 < 0.001

369 (133 – 901)

461 (113 – 1661)

0.5

 < 0.001